Manufacturing of [14C]-Labeled Drug Substance and Drug Product Utilized in Clinical Research: A Case Study of Omecamtiv Mecarbil

Author(s): Scott W. Roberts, Jeroen M. Bezemer, Michael T. Kennedy, Tiffany L. Correll, Raju Subramanian, Shawn D. Walker

Journal Name: Current Pharmaceutical Design

Volume 22 , Issue 5 , 2016

Become EABM
Become Reviewer
Call for Editor


This mini-review describes the Chemistry, Manufacturing and Control activities associated with the manufacture of [14C]-labeled drug substance and subsequent drug compounding activities to generate clinical trial material utilized in human absorption, distribution, metabolism, and excretion clinical studies. Due to the unstable nature and increased decomposition rates observed with [14C]-labeled compounds, the manufacture, testing, release, formulation, and regulatory filings are uniquely challenging. A case study of the cardiac myosin activator AMG 423 (omecamtiv mercarbil), utilized in a dual oral/intravenous infusion clinical study is presented.

Keywords: Chemistry, Manufacturing and Control (CMC), current Good Manufacturing Practice (cGMP), [14C]-Labeled Drug, Omecamtiv Mercarbil, AMG 423, human Absorption, Distribution, Metabolism, and Excretion (hADME), ICH Guidance, FDA Regulations.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Page: [609 - 615]
Pages: 7
DOI: 10.2174/1381612822666151228104826
Price: $65

Article Metrics

PDF: 37
PRC: 1